(Health Korea News / Lee Chang-yong) ‘Pharmaceutical 24 Hours’ is a corner that shows you at a glance the short news related to pharmaceuticals and biotechnology that you might easily miss. It may seem like trivial news, but it can be valuable information to someone, so we summarize only the facts and show you in an easy-to-understand manner.
HK inno.en, Ministry of Oceans and Fisheries Sign Business Agreement for ‘Non-face-to-face Island Doctor’
HK inno.en announced on the 22nd that it signed a business agreement for the ‘Non-face-to-face Island Doctor’ project with the Ministry of Oceans and Fisheries, the Korea Foundation for Large and Small Businesses, and the Korea Agricultural and Fisheries Cooperation Foundation to increase medical accessibility for island residents.
Through this business agreement, HK inno.en will contribute business funds and promote employee volunteer activities, and will also cooperate in donating medicine. It is expected to contribute to increasing medical accessibility for residents of island regions where it is difficult to receive medical benefits.
The ‘Non-face-to-face Island Doctor’ project led by the Ministry of Oceans and Fisheries was planned to contribute to improving accessibility to medical care by providing stable medical services to island residents in medical blind spots. It plans to build an island-only medical care system linked to non-face-to-face medical care services provided on smartphones to improve medical convenience such as prescription drug delivery, face-to-face medical care reservations, and medical record management.
Opdivoju Receives Additional Indication for Combination Therapy as First-Line Treatment for Patients with Uroepithelial Cell Carcinoma
Ono Pharmaceutical Korea and BMS Korea announced on the 17th that they received additional approval from the Ministry of Food and Drug Safety for the indication of the anti-PD-1 monoclonal antibody Opdivo (ingredient name: nivolumab) in combination with cisplatin and gemcitabine as the first-line treatment for unresectable or metastatic urothelial carcinoma.
This approval is for patients with previously untreated unresectable or metastatic urothelial carcinoma. It is based on the results of the phase 3 CheckMate-901 study (CA209-901: ONO-4538-56), which compared Opdivo monotherapy with cisplatin and gemcitabine after combination therapy with Opdivo plus cisplatin and gemcitabine.
The trial compared Opdivo monotherapy with platinum-based chemotherapy alone after combination therapy with Opdivo plus cisplatin and gemcitabine, demonstrating statistically significant and clinically meaningful improvements in the primary efficacy endpoints, overall survival (OS) and progression-free survival (PFS) as assessed by a blinded independent central review committee (BICR). The safety profile of Opdivo in this trial was consistent with previously reported data. No new safety information was provided.
Korea United Pharmaceuticals R&D Director Vice President Jeong Won-tae Holds Solo Painting Exhibition on the Theme of ‘Travel’
Vice President Jeong Won-tae, who oversees research and development at Korea United Pharmaceuticals, is holding a free solo tablet painting exhibition on the theme of ‘travel’ at the United Gallery.
Korea United Pharmaceuticals, specializing in improved new drugs, is actively spreading bright culture through various cultural and artistic activities such as classical performances and art gallery exhibitions as well as R&D investment. The company explained that this exhibition is drawing attention as it is a solo painting exhibition of Vice President Jeong Won-tae, who is in charge of Korea United Pharmaceuticals’ R&D including improved new drugs.
This exhibition, which will be held from the 7th to the 12th at the United Gallery located at 41 Gangnam-daero 102-gil, Gangnam-gu, Seoul, is decorated with works that Vice President Jeong Won-tae mainly drew domestic and international landscapes and short stories he encountered during his travels or business trips. Vice President Jeong Won-tae taught himself art and has been drawing various genres of art such as folk paintings, pen drawings, watercolors, and oil paintings on a tablet for several decades. Through this painting exhibition, “Travel,” the artist plans to reveal to the public his accumulated works, share his personal experiences while traveling with many people, and introduce his emotions as an artist and his interpretation of the works.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
